Abstracts tagged "lupus nephritis and outcomes"

Abstract Number: 1609 • 2019 ACR/ARP Annual Meeting
Organ Damage Free Survival in Southern Chinese Patients with Active Lupus Nephritis
Chi Chiu Mok¹, Chi Shan Sin ², Kai Ching Hau ² and Tse Hoi Kwan ², ¹Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the organ damage free survival and its predictive factors in patients with active LN.Methods: Consecutive patients who fulfilled ≥4 ACR/SLICC criteria for…
Abstract Number: 463 • 2018 ACR/ARHP Annual Meeting
Percentage of Glomerular Crescents Predicts Renal Outcomes in Childhood-Onset Lupus Nephritis
Pooja Patel¹, Marietta M. De Guzman¹, Joseph Maliakkal², Michelle Rheault³, David Selewski⁴, Katherine Twombley⁵, Jason Misurac⁶, Cheryl Tran⁷, Alexandru Constantinescu⁸, Ali Mirza Onder⁹, Meredith Seamon¹⁰, Vaishali Singh¹¹, Cynthia Pan¹¹, Joseph Flynn¹², Abiodun Omoloja¹³, William Smoyer¹⁴, Guillermo Hidalgo¹⁵ and Scott E. Wenderfer¹⁶, ¹Pediatrics-Rheumatology, Baylor College of Medicine, Houston, TX, ²Pediatrics-Renal, Saint Louis University, St. Louis, MO, ³Pediatrics-Renal, University of Minnesota, Minneapolis, MN, ⁴Pediatrics-Renal, University of Michigan, Ann Arbor, MI, ⁵Pediatrics-Renal, Medical University of South Carolina, Charleston, SC, ⁶Pediatrics-Renal, University of Iowa, Iowa City, IA, ⁷Pediatrics-Renal, Mayo Clinic, Rochester, MN, ⁸Pediatrics-Renal, Joe DiMaggio Children’s Hospital, Hollywood, FL, ⁹Pediatrics-Renal, University of Tennessee, Memphis, TN, ¹⁰Pediatrics-Renal, The University of Utah, Salt Lake, UT, ¹¹Pediatrics-Renal, Medical College of Wisconsin, Wauwatosa, WI, ¹²Pediatrics-Renal, Seattle Children's Hospital, Seattle, WA, ¹³Pediatrics-Renal, Wright State University, Dayton, OH, ¹⁴Pediatrics-Renal, Nationwide Children’s Hospital, Columbus, OH, ¹⁵Pediatrics-Renal, East Carolina University, Greenville, NC, ¹⁶Pediatrics-Renal, Baylor College of Medicine, Houston, TX
Background/Purpose: Outcomes for childhood-onset crescentic lupus nephritis are unclear. The revised classification system for lupus nephritis by the Renal Pathology Society clearly distinguishes between cellular,…
Abstract Number: 1616 • 2017 ACR/ARHP Annual Meeting
Early and Late Onset Biopsy Proven Lupus Nephritis without Other Associated Autoimmune Diseases: Severity and Long-Term Outcome
Michelle Lopes¹, Laryssa Santos², Luciana Seguro³ and Eloisa Bonfa⁴, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Lupus nephritis (LN) usually develops within the first years of Systemic Lupus Erythematosus (SLE) onset and rarely after that. There are scarce studies comparing…
Abstract Number: 1648 • 2017 ACR/ARHP Annual Meeting
Assessment of Outcome in Lupus Nephritis Patients: A Retrospective Analysis of a Single Center Cohort over 20 Years
Lihi Shemesh Eisen¹, Talia Weinstein², Irena Litinsky³, David Levartovsky¹, Ilana Kaufman¹, Marina Anouk⁴, Valerie Aloush⁴, Jonathan Wollman⁵, Jacob N. Ablin⁶, Uri Arad¹, Mark Berman¹, Victoria Furer¹, Ari Polachek⁷, Ofir Elalouf⁸, Sara Borok Lev-Ran¹, Reut Zemach⁹, Tali Eviatar¹, Michael Zisapel¹, Hagit Sarvagyl-Maman¹⁰, Dan Caspi¹¹, Ori Elkayam⁴ and Daphna Paran⁴, ¹Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ²Nephrology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ³Rheumatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁴Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine ,Tel-Aviv University, Tel-Aviv, Israel, ⁶Internal Medicine H, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Rheumatology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv Univrsity, Tel Aviv, Israel, ⁸Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁹Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ¹⁰Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, ¹¹Rheumatology, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
Background/Purpose: Lupus Nephritis (LN) is a severe SLE manifestation, leading to a six-fold increased risk of death. This study aims to assess the outcome of…
Abstract Number: 428 • 2016 ACR/ARHP Annual Meeting
Random Forest Models Using Electronic Health Record Data Are Predictive of One-Year Outcomes in Lupus Nephritis Patients Taking Mycophenolate Mofetil Induction Therapy
Bethany J Wolf¹ and Jim Oates^2,3, ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medical Service, Rheumatology Section, Ralph H. Johnson VAMC, Charleston, SC, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) outcomes are affected not only by patient biology but also by patient, provider, and system factors. One way to improve outcomes…
Abstract Number: 965 • 2016 ACR/ARHP Annual Meeting
Clinical and Serologic Variables Associated with Renal Response Among Lupus Nephritis Phase III Trial Patients Treated with Standard of Care Immunosuppression
Matthew D. Cascino¹, Peter Lambert², Anna Decker², Tamiko Katsumoto², Jay Garg², Paul Brunetta², Maria Dall'Era¹ and Leonard L. Dragone², ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Genentech, Inc., South San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is associated with high treatment failure rates and the development of new therapies for LN is limited by the lack of…
Abstract Number: 989 • 2015 ACR/ARHP Annual Meeting
Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis
Megan Barber¹, John G. Hanly², Aidan O'Keeffe³, Li Su⁴, Murray Urowitz^5,6, Yvan St. Pierre⁷, Juanita Romero-Diaz⁸, C. Gordon⁹, Sang-Cheol Bae¹⁰, Sasha Bernatsky¹¹, Daniel J Wallace¹², Joan T. Merrill¹³, David A. Isenberg¹⁴, Anisur Rahman¹⁵, Ellen M. Ginzler¹⁶, Paul R. Fortin¹⁷, Dafna D. Gladman¹⁸, Jorge Sanchez-Guerrero¹⁹, Michelle Petri²⁰, Ian N. Bruce²¹, Mary Anne Dooley²², Rosalind Ramsey-Goldman²³, Cynthia Aranow²⁴, Graciela S. Alarcon²⁵, W. Winn Chatham²⁶, Kristján Steinsson²⁷, Ola Nived²⁸, Gunnar K. Sturfelt²⁹, Susan Manzi³⁰, Munther Khamashta³¹, Ronald F. van Vollenhoven³², Asad Zoma³³, Manel Ramos-Casals³⁴, Guillermo Ruiz-Irastorza³⁵, S. Sam Lim³⁶, Thomas Stoll³⁷, Murat Inanc³⁸, Kenneth C. Kalunian³⁹, Diane L. Kamen⁴⁰, Peter Maddison⁴¹, Christine A. Peschken⁴², Søren Jacobsen⁴³, Anca Askanase⁴⁴, Jill P. Buyon⁴⁵, Chris Theriault⁴⁶, Kara Thompson⁴⁶, Vernon Farewell⁴⁷ and Ann E. Clarke⁴⁸, ¹Division of Rheumatology, University of Calgary, Caglary, AB, Canada, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Statistical Science, University College London, London, United Kingdom, ⁴MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK, Cambridge, United Kingdom, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁸Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutrición, Mexico City, Mexico, ⁹School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁰Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹¹Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ¹²Cedars-Sinai Medical Center, West Hollywood, CA, ¹³Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹⁵Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ¹⁶Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁷Rheumatology, University of Laval, Quebec, QC, Canada, ¹⁸Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²⁰Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²¹Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²²UNC Kidney Centre, Chapel Hill, NC, ²³Northwestern University Feinberg School of Medicine, Chicago, IL, ²⁴Feinstein Institute for Medical Research, Mahasset, NY, ²⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁶Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²⁷Centre for Rheumatology Research, Landspital University Hospital, Reykjavik, Iceland, ²⁸Rheumatology, Inst of Clinical sciences, Lund, Sweden, ²⁹Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ³⁰Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³¹Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³³Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³⁴Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ³⁵Autoimmune Disease Research Unit, Service of Internal Medicine, Hospital de Cruces, UPV/EHU, Barakaldo, Spain, ³⁶Emory University School of Medicine, Atlanta, GA, ³⁷Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, ³⁸Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁹Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ⁴⁰Medicine, Medical University of South Carolina, Charleston, SC, ⁴¹Musculoskeletal Medicine, Bangor University, Bangor, United Kingdom, ⁴²Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ⁴³Department of Rheumatology,, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁴⁴Columbia University College of Physicians & Surgeons, New York, NY, ⁴⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴⁶Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴⁷Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ⁴⁸Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Little is known about the long-term costs of lupus nephritis (LN). The annual and long-term healthcare costs were compared between SLE patients with and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].